BONE METABOLISM AND ITS REGULATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS
https://doi.org/10.14412/1995-4484-2016-527-529
Abstract
Osteoporosis in ankylosing spondylitis (AS) may exacerbate pain and functional disorders and increases the risk of fractures. The mechanisms of its development in AS have not been adequately studied.
Objective: to study bone mineral density (BMD) and its regulation in patients with AS.
Subjects and methods. 70 patients (mean age, 43.2±9.2 years) with a documented diagnosis of AS (mean disease duration, 17.1±7.8 years) and a control group of 30 healthy individuals were examined. All the patients underwent estimation of BMD and the serum concentrations of osteocalcin, CrossLaps, and key regulators of osteoclastogenesis, such as osteoprotegerin (OPG) and a receptor activator of nuclear factor kappa-B ligand (RANKL) by an enzyme immunoassay. Results and discussion. In patients with AS, bone metabolism was characterized by a decrease in bone formation and by some increase in bone tissue degradation especially in high AS activity. These patients showed the elevated levels of the major blocker of osteoclastogenesis OPG and the OPG/RANKL ratio, which can cause the process of ossification characteristic of AS.
About the Authors
O. V. Bugrova
Orenburg State Medical University
Russian Federation
Russian Federation
Olga Bugrova.
6, Sovetskaya St., Orenburg 460000
K. A. Nagornova
Orenburg State Medical University
Russian Federation
6, Sovetskaya St., Orenburg 460000
Russian Federation
6, Sovetskaya St., Orenburg 460000
N. E. Artemova
Orenburg State Medical University
Russian Federation
6, Sovetskaya St., Orenburg 460000
Russian Federation
6, Sovetskaya St., Orenburg 460000
References
1. Насонов ЕЛ, Скрипникова ИА, Насонова ВА. Проблема остеопороза в ревматологии. Москва: Стин; 1997. 778 с. [Nasonov EL, Skripnikova IA, Nasonova VA. Problema osteoporoza v revmatologii [The problem of osteoporosis in rheumatology]. Moscow: Stin; 1997. 778 p.].
2. Пирогова ОА, Раскина ТА, Летаева МВ. Низкая минеральная плотность кости как фактор риска развития остеопороза у мужчин, страдающих анкилозирующим спондилитом, и способы ее коррекции. Современная ревматология. 2014;8(3):45-50 [Pirogova OA, Raskina TA, Letaeva MV. Low bone mineral density as a risk factor for osteoporosis and ways of its correction in male patients with ankylosing spondylosis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2014;8(3):45-50. (In Russ.)]. doi: 10.14412/1996-7012-2014-3-45-50
3. Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. 752 с. [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical guidelines]. Moscow: GEOTAR-Media; 2010. 752 p.].
4. Шварц ГЯ. Молекулярно-биологические основы создания новых лекарственных средств для лечения остеопороза: Остеопротегерин, ЛОПГ (RANKL) и RANK: физиологический механизм регуляции костной резорбции. Остеопороз и остеопатии. 2003;(2):21-4 [Shvarts GYa. Molecular biological basis for the creation of new drugs for the treatment of osteoporosis: Osteoprotegerin, LOPG (RANKL), and the RANK: physiological mechanism of bone resorption regulation. Osteoporoz i Osteopatii. 2003;(2):21-4 (In Russ.)].
5. Lacey DL, Tirnms E, Tan IIL, el al. Osteoprotegerm ligand is a cytokine that regulates osteoclasts differentiation and activation. Cell. 1998;93(2):165-76. doi: 10.1016/S0092-8674(00)81569-X
6. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 Apr 18;89(2):309-19. doi: 10.1016/S0092-8674(00)80209-3
7. Беневоленская ЛИ. Руководство по остеопорозу. Москва: Бином. Лаборатория знаний; 2003. 524 с. [Benevolenskaya LI. Rukovodstvo po osteoporozu [Osteoporosis Guidelines]. Moscow: Binom. Laboratoriya Znaniy; 2003. 524 p.].
8. Grisar J, Bernecker PM, Aringcr M, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol. 2002;29(7):1430-6.
9. Картамышева НН, Чумакова ОВ. Костное ремоделирование как модель межклеточных взаимодействий (обзор литературы). Нефрология и диализ. 2004;6(1):43-6 [Kartamysheva NN, Chumakova OV. Bone remodeling as a model for cell-cell interactions (literature review). Nefrologiya i Dializ. 2004;6(1):43-6 (In Russ.)].
10. Лесняк ОМ, Беневоленская ЛИ, редакторы. Остеопороз. Клинические рекомендации. 2-е изд. Москва: ГЭОТАРМедиа; 2011. 272 с. [Lesnyak OM, Benevolenskaya LI, editors. Osteoporoz. Klinicheskie rekomendatsii [Osteoporosis. Clinical guidelines]. 2nd ed. Moscow: GEOTAR-Media; 2011. 272 p.].
11. Kim H-R, Kim H-Y, Lee S-H. Elevated serum levels of soluble receptor activator of nuclear factors-kB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis. J Rheumatol. 2006;45(10):1197-200. doi: 10.1093/rheumatology/kel072
Review
For citations:
Bugrova O.V., Nagornova K.A., Artemova N.E. BONE METABOLISM AND ITS REGULATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS. Rheumatology Science and Practice. 2016;54(5):527-529. (In Russ.) https://doi.org/10.14412/1995-4484-2016-527-529
Views:
816
Email this article 